A new EGFR inhibitor induces apoptosis in colon cancer cells

Biochemical and Biophysical Research Communications

Volumn 354, Issue 2, 2007, Pages 409-413

  Calonghi, N ^a   Pagnotta, E ^a   Parolin, C ^a   Mangano, C ^a   Bolognesi, M L ^a   Melchiorre, C ^a   Masotti, L ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Colon cancer; Confocal microscopy; EGFR; Tyrosine kinase

Indexed keywords

2 (8 AMINOOCTYLAMINO)[1,4]NAPHTHOQUINONE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FR 18; NAPHTHOQUINONE; SHIKONIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; MICROSCOPY, CONFOCAL; NAPHTHOQUINONES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846486205     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.214     Document Type: Article

References (18)

1. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther. 102 (2004) 37-46
2. Wells A. EGF receptor. Int. J. Biochem. Cell Biol. 31 (1999) 637-643
3. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 58 (2004) 1201-1208
4. Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer. Clin. Colorectal Cancer 3 (2004) 205-215
5. Needle M.N. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin. Oncol. 29 (2002) 55-60 Review
6. Diasio R.B., and Fourie J. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer. Drugs 66 (2006) 1441-1463
7. Baselga J., and Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs 60 (2000) 33-40
8. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., and Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6 (2000) 2053-2063
9. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 (2000) 4885-4892
10. Anido J., Matar P., Albanell J., Guzman M., Rojo F., Arribas J., Averbuch S., and Baselga J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9 (2003) 1274-1283
11. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., Kaye S.B., Gianni L., Harris A., Bjork T., Averbuch S.D., Feyereislova A., Swaisland H., Rojo F., and Albanell J. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20 (2002) 4292-4302
12. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., LoRusso P., Rischin D., Sauleda S., Gee J., Nicholson R.I., and Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20 (2002) 110-124
13. Guo X.P., Zhang X.Y., and Zhang S.D. Clinical trial on the effects of shikonin mixture on later stage lung cancer. Zhong Xi Yi Jie He Za Zhi 11 (1991) 580-599
14. Yoon Y., Kim Y.O., Lim N.Y., Jeon W.K., and Sung H.J. Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med. 65 (1999) 532-535
15. Singh F., Gao D., Lebwohl M., and Wei H. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett. 200 (2003) 115-121
16. Nakaya K., and Miyasaka T. A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases. Anticancer Drugs 14 (2003) 683-693
17. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., Reddy M.V., and Reddy E.P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 102 (2005) 1992-1997
18. Mickuviene I., Kirveliene V., and Juodka B. Experimental survey of non-clonogenic viability assays for adherent cells in vitro. Toxicol. In Vitro 18 (2004) 639-648